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How Do We Best Diagnose Malaria in Africa?
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Department of Medicine, University of California, San Francisco, California
For many decades, the cornerstone of malaria management
in Africa was to treat all febrile children with chloroquine.
Withhigh-levelresistancetochloroquineandimprovedmeans
ofmalariadiagnosis,recommendationsforthemanagementof
malaria in Africa have changed in two important ways in the
last few years. First, recommended therapy for uncomplicated
falciparum malaria has moved to highly effective artemisinin-
basedcombination therapies.
1 Second,it is now recommended
that the treatment of malaria be confined to parasitologically
confirmed cases. This recommendation requires the availabil-
ity of reliable diagnostic tests. The gold standard test for the
diagnosis of malaria is microscopy. Evaluation of Giemsa-
stained thick smears, when performed by expert microsco-
pists,providesaccuratediagnosisofmalaria,althoughassuring
expert slide preparation and reading can be difficult.
2 Indeed,
microscopy is often unavailable, especially in rural settings.
In this regard, the advent of rapid diagnostic tests (RDTs)
for malaria is an important advance. Multiple immunochro-
matographic tests, incorporating a number of different para-
site antigens and produced by many different manufacturers,
are now available.
3 At best, these tests offer a simple, fairly
inexpensive, and reliable means of diagnosis that can be per-
formed by healthcare workers with limited training. However,
concerns with RDTs include potential unreliability because
of inconsistent manufacture or poor storage, uncertain sup-
ply, and potential misreading of results by unskilled health
workers.Anadditional,generallyunappreciatedconcernwhen
consideringRDTsisdifferencesbetweenavailabletests.
RDTs for malaria are based principally on the detection of
one of three antigens, histidine-rich protein-2 (HRP2), lactate
dehydrogenase (LDH), and aldolase. These tests have impor-
tant differences. HRP2 is only expressed by Plasmodium falci-




HRP2 can circulate for an extended period of time after an
infection has been cleared
4 and is also expressed by gameto-
cytes.
5 Thus, false-positive tests may be caused by recent but
not current infection. LDH-based RDTs can be designed to
recognize only the P. falciparum antigen or those antigens
produced by all human malaria parasites. LDH tests are gen-
erally less sensitive than those tests directed against HRP2.
However, they may be more specific, because the antigen cir-
culates only briefly after eradication of infection.
4 In a study
from multiple sites in Uganda using microscopy as a gold stan-
dard, an HRP2-based assay offered improved sensitivity over
an LDH-based assay, and the negative predictive value of the
LDH-based test dropped significantly as transmission inten-
sity increased; thus, the HRP2-based test was recommended
for areas with medium to high levels of malaria transmis-
sion.
6 Genus-specific aldolase-based RDTs are also available;
these RDTs are offered with HRP2 detection to provide pan-
species diagnosis of malaria and diagnosis of falciparum
malariain a single test.
Surprisingly, the malaria control community seems to
pay quite little attention to the type of RDT that is used for
malaria diagnosis. World Health Organization (WHO) guide-
lines state that the tests “have different characteristics, which
may affect suitability for use in different situations,” but they
do not offer specific guidance as to the choice of test.
1 In prac-
tice, HRP2-based tests have been most widely used, with the
improved sensitivity of these tests considered more important
than their potential for loss of specificity because of identi-
fication of antigen after prior infections have been cleared.
Indeed, there is particular interest in avoiding false negatives,
because failure to treat a child with acute falciparum malaria
can have disastrous consequences. However, might the HRP2-
basedRDT alsoengender concerns regarding sensitivity?
In this issue of the journal, Koita and others
7 identify
another limitation of HRP2-based RDTs in Africa. Koita and
others
7 evaluated 480 blood samples from Mali that were
positive by standard malariamicroscopyandfoundthat26were
negative by HRP2-based RDT. All of these samples were posi-
tive for malaria based on repeat microscopy and polymerase
chain reaction (PCR) using primers that amplify conserved
P. falciparum sequences. However, for the 22 evaluable
samples, amplification of the HRP2 gene was successful for
only 12; 10 samples, thus, seemed to include P. falciparum
lacking an intact HRP2 gene. All of these samples contained
monoclonal infections, whereas most of the HRP2-positive
samples were polyclonal, supporting the existence in Mali of a
minority of P. falciparum parasites that do not express the
HRP2 gene. The results do not rule out the possibility that
these parasites expressed an altered HRP2 that was not recog-
nized by the RDT and whose gene was not amplified by stan-
dard primers. Regardless, these infections were not identified
by the RDT, pointing to definitive false negatives for this test.
Similarly, failure to amplify the HRP2 gene was recognized
previously in multiple P. falciparum samples from Peru.
8
The new work had some limitations.
7 First, it studied sam-
ples that were collected in 1996 and then stored for an undis-
closed number of years before PCR analysis, potentially
increasing the likelihood of false-negative assays for HRP2. It
is not clear if parasites from Mali and elsewhere in Africa are
more or less likely to be undetectable by HRP2-based RDT
at the present time. Second, only one set of primers was used
to detect the HRP2 gene in these samples. It is possible that
the gene was present in some or all of these samples but that
the primers could not detect the gene because of some varia-
tion in sequence. Third, all HRP2-negative infections in Mali
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192were asymptomatic. Symptomatic infections caused by HRP2-
negative parasites were noted in Peru,
8 but it is not clear if
such parasites can commonly cause illness among Africans,
who generallyhavehigh-level antimalarialimmunity.
Another limitation of HRP2-based RDTs is the inability
of these assays to identify nonfalciparum malaria infections.
Although the large majority of malaria infections are caused
by P. falciparum in sub-Saharan Africa, non-falciparum infec-
tions do play an important role. In a recent study of children
in an urban cohort in Kampala, Uganda, where parasite spe-
cies was determined by species-specific PCR, 94% of epi-
sodes of symptomatic malaria were caused by P. falciparum
(including mixed infections), but 4.6% were caused solely by
P. malariae, 0.8% were caused solely by P. ovale, and 0.5%
were caused solely by P. vivax.
9 Thus, in this setting, about
6% of episodes of malaria would be missed by an HRP2-
basedRDT. Importantly,thelandscapeofmalariaischanging.
Aggressive control efforts are leading to marked decreases in
the incidence of malaria and prevalence of malarial infection
at a number of locations in Africa.
10 These efforts may lead
to improved control of P. falciparum infection compared with
P. ovale and P. vivax infections, because the latter species are
not eliminated by most antimalarials because of lack of activ-
ity against chronic liver stages. Thus, with improving control,
more malaria infections may be caused by non-falciparum
parasites, and HRP2-based RDTs may have decreasing sensi-
tivityforthe diagnosis ofmalaria.
Considering the limitations of RDTs for malaria, what is
the appropriate course of action? One response would be
to return to reliance on a clinical diagnosis of malaria. This
approach might be reasonable in highly endemic areas, where
most fevers in children are caused by malaria,
11 but it will
lead to many inappropriate treatments and will clearly be less
desirable in areas with low to moderate or decreasing inci-
dence of malaria.
12 Another approach will be to rely fully on
microscopy and push this diagnostic modality into rural areas
with aggressive implementation and training efforts, which
has been successful in some areas.
13 However, it is unlikely
that reliable microscopy can be brought to all areas of rural
Africa, whereas RDTs can be used in nearly all clinical set-
tings. Therefore, most likely, consistent with WHO guidelines,
RDTs will increasingly be used for the diagnosis of malaria in
Africa. Which RDT should be used? First, it is important that
oversight of test manufacture, care in shipping and storage of
tests, and rigorous quality control lead to the consistent avail-
ability of high-quality tests. Second, serious consideration of
the optimal antigen for RDTs is warranted. The HRP2-based
RDT has been considered the best choice for Africa in large
part because of its high sensitivity, but increasing prevalence
of parasites that do not express HRP2 may challenge this
assumption. The sensitivity of HRP2-based RDTs is limited
because of their inability to recognize non-falciparum infec-
tions, and as described in the work by Koita and others
7 in
AJTMH, it also may be limited by the circulation of P. falci-
parum that does not express HRP2. These results suggest that
the optimal RDT for Africa may need to be reconsidered. In
particular, additional study of the sensitivity of HRP2-based
and other RDTs is needed, and if the prevalence of HRP2-
negative P. falciparum parasites or non-falciparum malaria
parasites is increasing, the use of RDTs recognizing antigens
other than HRP2 may be advisable.
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